Physician profile
Mohammad Ali
NPI 1326484783
$1,879.73
in general payments reported to CMS, 2019-2025
20 companies · $136 in 2025
The $136 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $201 · 2021: $263 · 2022: $194 · 2023: $195 · 2024: $522 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $619.95 | 2019-2024 | Xarelto, Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $261.96 | 2019-2025 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $254.01 | 2024 | Voquezna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $93.76 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.06 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.69 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $60.94 | 2022 | |
| Gilead Sciences, INC. | $55.78 | 2024 | |
| Alexion Pharmaceuticals, INC. | $47.19 | 2019-2021 | |
| Abbvie INC. | $46.59 | 2023 | Teflaro |
| Novartis Pharmaceuticals Corporation | $42.50 | 2019-2021 | |
| Pfizer INC. | $33.53 | 2023-2025 | |
| Glaxosmithkline, LLC. | $33.31 | 2019-2020 | |
| Melinta Therapeutics, LLC | $33.10 | 2024 | Rezzayo |
| Lilly USA, LLC | $31.64 | 2023 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $22.65 | 2023 | Opsumit |
| Shionogi INC | $22.62 | 2024 | Fetroja |
| Biogen, INC. | $21.86 | 2024 | Tysabri, Vumerity |
| Epizyme, INC. | $20.46 | 2022 | |
| Kerecis Limited | $17.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.